Raman Arun K, Fakih Marwan G
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Chemotherapy. 2007;53(4):306-8. doi: 10.1159/000103249. Epub 2007 May 25.
Headaches have been reported as a potential side effect of capecitabine therapy. However, severe limiting headaches are rarely experienced in this setting and no known therapy has been described for such a serious side effect.
We report the case of a patient treated with capecitabine and radiation for rectal adenocarcinoma. The patient developed grade 3 capecitabine-induced headache. A cause-effect relationship to capecitabine was suggested due to resolution of headache with capecitabine withdrawal and reappearance with capecitabine rechallenge. The patient's headache resolved with diltiazem therapy and she was able to complete capecitabine and radiation therapy without further adverse events.
Capecitabine and 5-fluorouracil (5-FU) are known vasospasm inducers. We hypothesize that capecitabine-induced headache is vascular in nature. This likely explains the noted response to a calcium channel blocker (CCB), namely diltiazem. CCBs should be considered in the treatment of 5-FU or capecitabine-induced headaches.
据报道,头痛是卡培他滨治疗的一种潜在副作用。然而,在这种情况下很少出现严重的、限制治疗的头痛,并且对于这种严重的副作用尚无已知的治疗方法。
我们报告了一例接受卡培他滨和放疗治疗直肠腺癌的患者。该患者出现了3级卡培他滨诱发的头痛。由于停用卡培他滨后头痛缓解,再次使用卡培他滨后头痛复发,提示头痛与卡培他滨存在因果关系。患者的头痛通过地尔硫䓬治疗得以缓解,并且她能够完成卡培他滨和放疗治疗,未再出现其他不良事件。
卡培他滨和5-氟尿嘧啶(5-FU)是已知的血管痉挛诱导剂。我们推测卡培他滨诱发的头痛本质上是血管性的。这可能解释了对钙通道阻滞剂(CCB),即地尔硫䓬的显著反应。在治疗5-FU或卡培他滨诱发的头痛时应考虑使用CCB。